JPRN-jRCT2031210061招募中3 期
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients with Atypical Hemolytic Uremic Syndrome (aHUS)
Camelia Sima0 个研究点目标入组 90 人开始时间: 2021年4月27日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Body weight >=40 kg at screening
- •Vaccination against Neisseria meningitidis
- •Participants with a prior kidney transplant are eligible if they have a know history of complement-medical aHUS prior to the kidney transplant.
排除标准
- •TMA associated with non-aHUS related renal disease
- •Positive direct Coombs test
- •Chronic dialysis and/or end stage renal disease
研究者
相似试验
招募中
1 期
A Study Evaluating the Efficacy and Safety of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS)CTIS2023-505089-27-00F. Hoffmann-La Roche AG81
招募中
1 期
A Study Evaluating the Efficacy and Safety of Crovalimab in Pediatric Patients with Atypical Hemolytic Uremic Syndrome (aHUS)CTIS2023-505638-82-00F. Hoffmann-La Roche AG38
进行中（未招募）
1 期
An Open Study of the Efficacy and Safety of a new drug in Patients with Bladder Canceron-Muscle Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005948-29-BGroGen Pharma Ltd.220
招募中
1 期
An Open Study of the Efficacy and Safety of a new drug in Patients with Bladder Canceron-Muscle Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005948-29-LTroGen Pharma Ltd.220
招募中
1 期
An Open Study of the Efficacy and Safety of a new drug in Patients with Bladder CancerEUCTR2021-005948-29-ATroGen Pharma Ltd.220